Results 11 - 18 of 18 : Previous 1 2
Stricter standards at the FDA could create a Foolish opportunity.
Another Headache for Pozen Investors
The drugmaker might have to run one more trial for the FDA for its migraine drug.
This Just In: Upgrades and Downgrades
Mixed signals on Ceragon Networks.
If its latest drug isn't approved, the pharmaceutical could face trouble.
Go hunting for misunderstood multibaggers in the making.
Don't Let Bad Math Ruin Your Retirement
A few miscalculations can wreck a lifetime of saving and investing.
It's a good time to buy shares, because a headache drug could be on its way to the market.
Big news is in the offing for these companies.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK